The clinical analysis of haploidentical stem cell transplantation in myelodysplastic syndrome-associated acute myeloid leukemia / 中华血液学杂志

ABSTRACT

Objective@#To investigate the prognosis of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).@*Method@#The data of 102 patients with high-risk AML in the first complete remission phase (CR1) who received haplo-HSCT from January 2009 to July 2015 in Peking University People's Hospital were retrospectively analyzed.@*Results@#These 102 cases included 17 AML-MRC cases (AML-MRC group) and 85 other types of AML cases (control group). There were 8 males and 9 females in the AML-MRC group, and the median age was 35 (17-61) years. There were 52 males and 33 females in other high-risk AML group, and the median age was 31 (11-60) years. No difference was observed between the two groups after haploidentical stem cell transplantation in the rates of cytomegalovirus, EBV (Epstein-Barr virus), blood flow infection rate and hematopoietic reconstitution (P>0.05). The overall 2-year survival rate after transplantation was 80.8% (95%CI 51.6%-93.4%) and 72.5% (95%CI 62.8%-80.1%) (P=0.650), the disease-free survival rate was 79.4% (95%CI 48.8%-92.9%) and 65.9% (95%CI 54.3%-75.2%) (P=0.573), cumulative recurrence rate was 13.0%(95%CI 1.9%-34.7%) and 13.3%(95%CI 7.0%-21.5%) (P=0.623), and non-relapse mortality was 6.7% (95%CI 0.3%-27.0%) and 20.0% (95%CI 12.0%-29.4%) (P=0.436).@*Conclusion@#The prognosis of haplo-HSCT in patients with AML-MRC in CR1 is similar to that of other types of high-risk AML patients. Haplo-HSCT is an ideal choice for patients with AML-MRC in CR1.